High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Authors: Pellicelli A et al
Date: May 20
Scope of interest: infectious/hepatological
06 99 39
Recup number
You may also be interested in:
Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study.
Authors: lionetti R
Date: May 2019
Scope of interest: infectious/hepatological
Read details
Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma
Authors: Giannini EG et al.
Date: Jan 2016
Scope of interest: hepatological
Read details
Erratum to: Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel.
Authors: ranieri r et al
Date: Apr 17, 2023
Scope of interest: infectious diseases/penitentiary health
Read details
What to do to
Click on the icon of the service you are looking for and go to the dedicated section. If the service is not in the selection, go to Service Guide
